[ Main Page | Editorial Board | About | Instructions ]
[ Table of Contents | Archive | Archive Search | Online Submission | Sponsor | E-mail ]

Turkish Journal of Cancer
1997, Volume 27, Number 3, Page(s) 91-97
[ Summary ]
Combination chemotherapy involving weekly epirubicin in the treatment of intermediate and high grade non-Hodgkin’s lymphomas
DİLEK DİNÇOL, NİL MANDEL MOLİNAS, İBRAHİM BARIŞTA, GÜRSEL AKTAN, HALUK ONAT, ORHAN SEYFİ SARDAŞ, ÖNDER BERK, CAVİT ÇEHRELİ, DİNÇER FIRAT
Turkish Oncology Group (TOG)*

To improve the outcome of patients with advanced stage intermediate or high grade non-Hodgkin’s Iymphomas, a combination chemotherapy including cyclophosphamide, vincristine, prednisone and weekly epirubicin was administered to forty-one consecutive patients in this multicenter prospective clinical trial. Of thirty-three evaluable patients, 25 (76%) had complete remission and 4 (12%) had partial remission. Ten relapses occurred in the group with complete remission. Projected two-year disease-free and overall survival rates were 47% and 52%, respectively. Mean weekly epirubicin dose was 27.8 mg/m2 in 14 patients in whom dose escalation was made. Cardiac toxicity was detected in five patients. Two treatment related deaths were observed due to neutropenic sepsis and late cardiac toxicity. In conclusion, the high response rates obtained with this weekly epirubicin containing regimen suggest that this combination may be a good alternative to doxorubicin based regimens as induction chemotherapy, but late cardiac toxicity should be taken into consideration.

[ Summary ]
Turkish Journal of Cancer web sitesi Novartis Onkoloji'nin karşılıksız eğitim katkılarıyla hazırlanmıştır.
[ Main Page | Editorial Board | About | Instructions ]
[ Table of Contents | Archive | Archive Search | Online Submission | E-mail ]